Med. praxi. 2013;10(4):139-141

Treatment options of resistant hypertension

doc.MUDr.Věra Čertíková Chábová, Ph.D.
Klinika nefrologie 1. lékařské fakulty a Všeobecné fakultní nemocnice, Praha

Resistant hypertension is defined as hypertension that remains uncontrolled despite treatment with three different optimally dosed

antihypertensive agents, one of which is a diuretic. Prior to making a definitive diagnosis, it is necessary to rule out pseudoresistance

that is often caused by the fact that the patient is not taking medications as prescribed. It is also of importance to eliminate factors that

increase blood pressure, such as excessive salt intake and use of medications and other substances causing hypertension. Not uncommonly,

resistance may occur in secondary hypertension due to obesity, sleep apnoea syndrome, vascular and endocrine diseases, or

intracranial tumours. Medications must always contain an appropriately selected diuretic at a sufficient dose. In clinical trials today, it is

also possible to use nonpharmacological strategies, such as renal denervation or stimulation of the carotid sinus.

carotid sinus stimulation.

Keywords: resistant hypertension, secondary hypertension, hypertension management, diuretics, catheter-based renal denervation,

Published: April 15, 2013  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Čertíková Chábová V. Treatment options of resistant hypertension. Med. praxi. 2013;10(4):139-141.
Download citation

References

  1. Carey RM. Resistant hypertension. Hypertension. 2013; 61: 746-750. Go to original source... Go to PubMed...
  2. Brown MA, Buddle ML, Martin A. Is resistant hypertension really resistant? Am J Hypertens. 2001; 14: 1263-1269. Go to original source... Go to PubMed...
  3. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-to-control arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011; 34: 87-90. Go to original source... Go to PubMed...
  4. Štrauch B, Chytil L, Kurcová I, et al. Jak posoudit non-compliance k farmakoterapii u těžké rezistentní hypertenze? Cor et Vasa. 2011; 53: 429-432. Go to original source...
  5. Aghamohammadzadeh R, Heagerty AM. Obesity-related hypertension: epidemiology, pathophysiology, treatments, and the contribution of perivascular adipose tissue. Ann Med. 2012; 44(Suppl 1): S74-84. Go to original source... Go to PubMed...
  6. Fan AZ, Li Y, Elam-Evans LD, Balluz L. Drinking pattern and blood pressure among non-hypertensive current drinkers: findings from 1999-2004 National Health and Nutrition Examination Survey. Clin Epidemiol. 2013; 5: 21-27. Go to original source... Go to PubMed...
  7. Horký K. Snížení obsahu soli v potravě - opomíjený postup v prevenci a léčbě hypertenze v populaci. Vnitr Lek. 2009; 55: 797-801. Go to PubMed...
  8. Holaj R. Arteriální hypertenze navozená léky a rezistence na antihypertenzní terapii. Medical Tribune, 2010. Dostupné na http://www.tribune.cz/clanek/28188-arterialni-hypertenze-navozena-leky-a-rezistence-na-antihypertenzni-terapii.
  9. Rajagopalan N. Obstructive sleep apnea: not just a sleep disorder. J Postgrad Med. 2011; 57: 168-175. Go to original source... Go to PubMed...
  10. van Jaarsveld BC, Krijnen P, Pieterman H, et al. The effect of balloon angioplasty on hypertension in atherosclerotic renal-artery stenosis. Dutch Renal Artery Stenosis Intervention Cooperative Study Group. N Engl J Med. 2000; 342: 1007-1014. Go to original source... Go to PubMed...
  11. Ives NJ, Wheatley K, Stowe RL, et al. Continuing uncertainty about the value of percutaneous revascularization in atherosclerotic renovascular disease: a meta-analysis of randomized trials. Nephrol Dial Transplant. 2003; 18: 298-304. Go to original source... Go to PubMed...
  12. Textor SC, Lerman L. Renovascular hypertension and ischemic nephropathy. Am J Hypertens. 2010; 23: 1159-1169. Go to original source... Go to PubMed...
  13. Fardella CE, Mosso L, Gómez-Sánchez C, et al. Primary hyperaldosteronism in essential hypertensives: prevalence, biochemical profile, and molecular biology. J Clin Endocrinol Metab. 2000; 85: 1863-1867. Go to original source...
  14. Mosso L, Carvajal C, González A, et al. Primary aldosteronism and hypertensive disease. Hypertension. 2003; 42: 161-165. Go to original source... Go to PubMed...
  15. Strauch B. Primární aldosteronismus, nejčastější forma sekundární hypertenze. Postgraduální medicína 2010: 964-969.
  16. Sacerdote A, Weiss K, Tran T, Rokeya Noor B, McFarlane SI. Hypertension in patients with Cushing's disease: pathophysiology, diagnosis, and management. Curr Hypertens Rep. 2005; 7: 212-218. Go to original source... Go to PubMed...
  17. Widimský J, Zelinka T, Petrák O, et al. Feochromocytom: diagnostika a léčba. Cas Lek Cesk. 2009; 148: 365-369. Go to PubMed...
  18. Tomaschitz A, Ritz E, Pieske B, et al. Aldosterone and parathyroid hormone: a precarious couple for cardiovascular disease. Cardiovasc Res. 2012; 94: 10-19. Go to original source... Go to PubMed...
  19. Calhoun DA, Jones D, Textor S, et al. Resistant hypertension: diagnosis, evaluation, and treatment. A scientific statement from the American Heart Association Professional Education Committee of the Council for High Blood Pressure Research. Hypertension. 2008; 51: 1403-1419. Go to original source... Go to PubMed...
  20. Hypertension ESo. Guidelines for the Management of Arterial Hypertension. Dostupné na http://www.eshonline.org/Guidelines/ArterialHypertension.aspx.
  21. Filipovský J, Widimský J, Ceral J, et al. Diagnostické a léčebné postupy u arteriální hypertenze - verze 2012. Doporučení České společnosti pro hypertenzi. Vnitr Lek. 2012; 58: 785-801. Go to PubMed...
  22. Hermida RC, Ayala DE, Fernández JR, Calvo C. Chronotherapy improves blood pressure control and reverts the nondipper pattern in patients with resistant hypertension. Hypertension. 2008; 51: 69-76. Go to original source... Go to PubMed...
  23. Messerli FH, Makani H, Benjo A, Romero J, Alviar C, Bangalore S. Antihypertensive efficacy of hydrochlorothiazide as evaluated by ambulatory blood pressure monitoring: a meta-analysis of randomized trials. J Am Coll Cardiol. 2011; 57: 590-600. Go to original source... Go to PubMed...
  24. Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: systematic review and network meta-analyses. Hypertension. 2012; 59: 1110-1117. Go to original source... Go to PubMed...
  25. Bash L, Astor B, Coresh J. Risk of incident ESRD: a comprehensive look at cardiovascular risk factors and 17 years of follow-up in the Atherosclerosis Risk in Communities (ARIC) Study. Am J Kidney Dis. 2010; 55: 31-41. Go to original source... Go to PubMed...
  26. Esler MD, Krum H, Schlaich M, et al. Renal sympathetic denervation for treatment of drug-resistant hypertension: one-year results from the Symplicity HTN-2 randomized, controlled trial. Circulation. 2012; 126: 2976-2982. Go to original source... Go to PubMed...
  27. Widimský P, Filipovský J, Widimský Jj, Branny M, Monhart V, Táborský M. Odborné stanovisko České kardiologické společnosti a České společnosti pro hypertenzi k provádění katetrizačních renálních denervací (RDN) v České republice. Hypertenze a kardiovaskulární prevence 2012; 1: 5-9.
  28. Alnima T, de Leeuw PW, Kroon AA. Baroreflex activation therapy for the treatment of drug-resistant hypertension: new developments. Cardiol Res Pract. 2012; 2012: 5871-5894. Go to original source... Go to PubMed...
  29. Bisognano JD, Bakris G, Nadim MK, et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol. 2011; 58: 765-773. Go to original source... Go to PubMed...
  30. Scheffers IJ, Kroon AA, Schmidli J, et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol. 2010; 56: 1254-1258. Go to original source... Go to PubMed...




Medicine for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.